Agenus (NASDAQ:AGEN) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research report sent to investors on Wednesday morning,Benzinga reports.

Agenus Trading Up 11.0 %

NASDAQ AGEN opened at $1.86 on Wednesday. The company’s fifty day simple moving average is $3.17 and its 200-day simple moving average is $3.80. Agenus has a 52 week low of $1.65 and a 52 week high of $19.69. The stock has a market cap of $43.63 million, a P/E ratio of -0.17 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. On average, research analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Trading of Agenus

Several institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG raised its holdings in Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 51,566 shares in the last quarter. Corton Capital Inc. acquired a new stake in Agenus in the fourth quarter valued at $36,000. Bank of America Corp DE raised its holdings in Agenus by 34.0% in the fourth quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock valued at $294,000 after acquiring an additional 27,157 shares in the last quarter. Jane Street Group LLC raised its holdings in Agenus by 97.6% in the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after acquiring an additional 52,215 shares in the last quarter. Finally, B. Riley Financial Inc. bought a new stake in Agenus during the fourth quarter valued at $2,074,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.